IMMUNOME INC (IMNM) Stock News
NASDAQ:IMNM - Nasdaq - US45257U1088 - Common Stock - Currency: USD
IMNM Latest News, Press Relases and Analysis
These stocks are moving in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immunome to Present at Upcoming Investor Conferences
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates
Immunome (IMNM) delivered earnings and revenue surprises of 21.21% and 28.33%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CDXS
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates
Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of 14.71% and 19.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BOLT
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
The analyst behind the change is now bullish on Teva's future. A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries's (NYSE: TEVA) well higher on Monday. The company, known for being a top producer of generic drugs, saw its share price swell almost 6% as a result.
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade
The consensus price target hints at a 249.9% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome to Present at Upcoming March Conferences
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Announces Pricing of Upsized Public Offering of Common Stock
Immunome Announces Proposed Public Offering of Common Stock
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 Small-Cap Stocks With Big Growth Potential
Small-cap companies may give investors more targeted exposure to the U.S. economy; these companies are three leaders in the space.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
